Aureobasidium.org

patent 2023

Biological healing accelerator-EU (European Patent No. 2630961)

Iwai A., Uchiyama H. · European Patent Office
Research Archive
TL;DR — Key Findings
  • EU patent for AP β-glucan as biological healing accelerator (second application).
  • European IP coverage reflects strong international patent portfolio for AP-glucan healing.
  • Multiple EU patents reinforce AP-glucan's commercial value in wound healing applications.

Abstract

Biological healing accelerator-EU (European Patent No. 2630961)

Patent Details

Country of RegistrationEurope

Patent No.No. 2630961Registration DateNovember 26, 2014Remarks※ Promotion of “wound” healing

Currently, Aureobasidium (black yeast) culture medium (hereafter referred to as “Aureo culture medium”) has been approved in Japan, Europe (UK, France, Germany), China, Hong Kong, Taiwan, and Thailand to reduce the side effects of anticancer drugs and to promote healing of erythema caused by burn wounds.

Summary

Summary

Patent Overview

European Patent No. 2630961 is a continuation/divisional patent covering additional claims for Aureobasidium pullulans-derived β-glucan as a biological healing accelerator. This patent expands protection for specific formulations and therapeutic applications of N-163 β-glucan in biological tissue healing and recovery.

Significance

This second EU patent (complementing EP 2098240) provides broader and more specific intellectual property coverage for the biological healing acceleration technology based on A. pullulans-derived β-glucan across European markets.

Citation

Iwai A., Uchiyama H.. Biological healing accelerator-EU (European Patent No. 2630961). European Patent Office. 2023.

Study Details
Study Type
patent
Published
2023
Journal
European Patent Office
Authors
Iwai A., Uchiyama H.
Important Notice

For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.